Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2022 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q1: 2022-05-09 Earnings Summary

EPS of -$0.59 misses by $0.32
 | Revenue of $2.04M (18,409.09% Y/Y) misses by $15.20M

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET

Company Participants

Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications
Anna Protopapas - President, CEO & Director
Arvin Yang - Senior VP & Chief Medical Officer
Tim Lowinger - Chief Science & Technology Officer
Brian DeSchuytner - Senior VP & CFO

Conference Call Participants

Jonathan Chang - SVB Leerink
Boris Peaker - Cowen
Daniel Wolle - JPMorgan
Colleen Kusy - Baird
David Nierengarten - Wedbush Securities

Operator

Good morning, and welcome to Mersana Therapeutics First Quarter 2022 Conference Call and webcast. Currently all participants are in a listen-only mode. There will be a question answer session at the end of this call.

I would now like to turn the call over to Jason Fredette, Senior Vice President, Investor Relations and Corporate Communications. Please proceed.

Jason Fredette

Good morning, everyone. Before we begin, I'd like to mention that our call will contain forward-looking statements within the meaning of the federal securities laws. These statements include, but are not limited to, those related to the company's business strategy, platform potential, clinical trial or preclinical study execution and data releases, regulatory plans and objectives, commercial opportunities and cash runway. Each of these forward-looking statements is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements.

These risks and uncertainties are discussed in the company's annual report on Form 10-K filed with the Securities and Exchange Commission or SEC on February 28, 2022, and in subsequent SEC filings. These documents are available at sec.gov or on our website, mersana.com. Except as required by law, we assume no obligation to update forward-looking statements publicly even if new information becomes available in the future.

With that, let me turn the

Recommended For You

About MRSN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on MRSN